GREENFIELD, Wis., April 16, 2017 -- Greenfield Veterinary Clinic announced the development of a new injectable treatment to fight canine itch. This problem, technically known as atopic dermatitis, causes dogs to scratch and bite themselves raw even in the absence of typical triggers like fleas. The raw areas can then become infected, causing even more problems. On top of that, the constant agitation is bad for the dogs' overall health as well as the anxiety levels of their human companions.
Previous solutions for canine itch included special baths and oral medications. Unfortunately, these medications often cause significant side-effects that make them unsuitable for continued use. The baths are typically tolerated better, but many pet owners also complain that they aren’t effective. On top of that, bathing a dog can be a big job, especially if it’s a large breed.
"We are very excited to offer this new technology to our canine friends," says Dr. James Work, owner and senior doctor at Greenfield Veterinary Clinic. "Prior to this development, previous itch medications resulted in side effects that were undesirable. Although this new therapy may not be appropriate for every itchy dog, we invite you to call us or to schedule an appointment to see if it will be beneficial for your pet.”
This new treatment is not yet available at all veterinary clinics. A select few have been given the USDA's special permission to dispense it. This is an immunotherapy treatment rather than one meant to cancel the effects of a specific allergen, which makes this a versatile treatment for dogs with canine itch, regardless of what caused their reaction.
Veterinary clinics that have obtained this permission aren't limiting themselves to this particular medication. Greenfield Veterinary Clinic, for example, still offers their regular variety of treatments along with this new innovation. This is partly because some pets will need something other than the injectable solution. As with any treatment, patients must be matched with the right medication after a proper examination.
With this new treatment option, many dogs who have endured canine atopic dermatitis for 30 days or more will be able to be relieved of canine itch. Those who have pets that haven't responded to other treatments are encouraged to check with Greenfield Veterinary Clinic about this development.
About Greenfield Veterinary Clinic
Greenfield Veterinary Clinic treats cats, dogs, and other common domesticated pet species in the Oak Creek and greater Milwaukee area. They have been in business for almost 20 years and are headed by veterinarians Dr. James Work, Dr. Christian Taylor, and Dr. Sarah Sylla.
Additional information on their hours, services, and location can be found on their website at http://greenfieldpetvet.com/. First-time clients may be eligible for a complimentary initial exam.
Greenfield Veterinary Clinic 5981 S 27th St. Greenfield, WI 53221 (414) 282-5230


Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 



